Microba to move into the US medical market 

Five Queensland start-ups specialising in medical technology and therapeutics have touched down in San Francisco, one of the world’s life sciences hot spots, to begin training with the prestigious California Life Sciences Institute (CLSI).

The move is part of a new start-up acceleration program coordinated by Trade and Investment Queensland (TIQ) and Life Sciences Queensland Limited (LSQ). Premier Annastacia Palaszczuk congratulated the chosen companies for being awarded a fully-funded place in a new start-up acceleration program.

“These five companies will receive coaching in market analysis, legal requirements, pitching to investors and finance, and gain access to their own in-market mentor network, accelerating their successful entry into the North American market,” Ms Palaszczuk said. 

“I’m confident it will prove fertile ground for these Queensland innovators to progress their export and investment plans with North American partners,” Ms Palaszczuk said.

The five companies will be in San Francisco from 14-18 October 2019, returning in January 2020. They will also attend the BIO International Convention in San Diego in June 2020.

Participating companies:

• Microba – gut microbiome testing and analysis
• De Motu Cordis – innovative medical technologies for rapid drug delivery in emergency care
• Ellume Health – digital diagnostics
• Field Orthopaedics – innovative medical devices for orthopaedic applications
• Zucero Therapeutics – modified sugar compounds to treat cancer and inflammatory conditions.

See here for more information.